The emerging market for nonpsychotropic products from the cannabis plant was the topic of a recent “MTSU On the Record” radio program.
Host Gina Logue’s interview with Dr. Elliot Altman, a professor of biology and director of the Tennessee Center for Botanical Medicine Research at MTSU, first aired March 19 on WMOT-FM Roots Radio 89.5 and online at www.wmot.org. You can listen to their conversation above.
Altman sorts out the difference between CBD, a safe nonaddictive substance unique to cannabis, and THC, the active ingredient which induces a “high” in the marijuana user. Both substances are being studied by scientists for their therapeutic properties. Proponents of CBD cite its possible use in relieving chronic pain, anxiety and other conditions.
“THC is a psychotropic, and it’s being used as alternative pain management, very effectively so by the medical marijuana states,” Altman said.
“CBD is a nonpsychotropic … and there are a number of scientific and medical studies that are starting to show that … CBD is good … as an anti-inflammatory agent, … and it also works well against epileptic conditions.”
The Tennessee Center for Botanical Medicine Research has a $2.5 million, 10-year grant from Greenway Herbal Products to study cannabinoids.
To hear previous “MTSU On the Record” programs, visit the searchable “Audio Clips” archives at www.mtsunews.com.
For more information about “MTSU On the Record,” contact Logue at 615-898-5081 or WMOT-FM at 615-898-2800.
COMMENTS ARE OFF THIS POST